Rousselot, Darling Elements’ collagen and gelatin model, has reported promising preclinical outcomes from a examine carried out by Cellbricks Therapeutics, a Berlin-based biotech startup and spin-off from the Technical College of Berlin. As a pioneer in 3D bioprinting, Cellbricks efficiently implanted 3D bioprinted adipose tissue constructs into mice, with no indicators of fibrosis or rejection noticed after seven weeks.
A key hurdle in regenerative drugs is reaching transplanted cell survival and integration with host tissues whereas minimizing immune responses. To deal with this, Cellbricks integrated Rousselot’s medical-grade biomaterials – particularly, purified gelatins – which performed a pivotal position in enhancing each the structural and useful efficiency of the bioink used within the constructs.
“The purity, consistency, and biocompatibility of Rousselot gelatin have been key to the success of our venture,” mentioned Alexander Thomas, Tender Tissue Program Chief at Cellbricks. “We noticed speedy tissue integration and vascularization that led to the formation of viable fatty tissue within the constructs – key indicators of profitable long-term grafting.”
“Cellbricks’ pioneering work in organ and tissue printing, mixed with Rousselot’s high-quality biomaterials, can symbolize a major step ahead in regenerative drugs. This achievement displays how collaboration round medical-grade biomaterials and superior bioprinting can speed up progress in tissue engineering, supply of cell therapies, and organ printing,” mentioned Tanja Vervust, World Director Biomedical at Rousselot.
